CTP Imaging of Lung Cancer

NCT ID: NCT01823094

Last Updated: 2016-01-26

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 14 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-03-31
• Study Completion Date: 2015-06-30

Brief Summary

Investigators hope to learn more about how to use computed tomography (CT) scans to measure blood flow in lung tumors and how it may change in response to treatment. This measurement technique is called computed tomography perfusion (CTP). CT scanners use X-rays to produce 3-dimensional images of the body.

Currently, doctors determine the response to treatment by measuring the size of the tumor. Investigators are trying to find out if measuring the blood flow in the tumor is equal to or better than measuring the size of the tumor.

Detailed Description

This is an experimental study of CT perfusion (CTP) imaging in subjects with non-small cell lung cancer. The objectives of this study are to demonstrate the feasibility of CT blood flow measurements in lung cancer, to develop a foundation for the use of CT blood flow measurements in lung cancer to assess the response to treatment, and to develop an optimized CTP imaging protocol for evaluating blood flow in solid body tumors. In this study, tumor blood flow will be evaluated at baseline and follow-up routine CT examinations of patients with non-small cell lung cancer, and the response of tumor blood flow will be recorded as a secondary endpoint. This research study will entail two study visits - one required and one optional - which will coincide with regularly scheduled standard of care CT scans.

Conditions

Non Small Cell Lung Cancer

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Study Groups

Variability of measurements

variability of CTP measurements will be determined by repeating the CTP examination, and comparing the resultant blood flow estimates

No interventions assigned to this group

Treatment induced effects

The magnitude of treatment induced effects will be assessed by comparing tumor blood flow estimates before and after treatment

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

adult patients with non small cell lung cancer who receive, or are considered for, systemic therapy

Exclusion Criteria

renal failure pregnancy known contrast allergy

-

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Radiological Society of North America

OTHER

Sponsor Role: collaborator

University of California, Davis

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Friedrich Knollmann, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Univeristy of California, Davis

Locations

University of California, Davis Medical Center

Sacramento, California, United States

Countries

United States

Other Identifiers

393991

Identifier Type: -

Identifier Source: org_study_id